Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Cholangiocarcinoma 6Carcinoma, Transitional Cell 5Acrocephalosyndactylia 5Neoplasm Metastasis 3Gastrointestinal Neoplasms 3Breast Neoplasms 3Recurrence 2Pancreatic Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solid Tumor, Miscellaneous 1Solid Tumor 1Sarcoma 1Oligodendroglioma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms 1Myeloproliferative Disorders 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lung Neoplasms 1Locally Advanced Unresectable Gastric Cancer 1Liposarcoma 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1

Interventions

Docetaxel 5S 1 (combination) 2Carboplatin 2zimberelimab 1surufatinib 1quemliclustat 1pemigatinib 1nimotuzumab 1lorlatinib 1cemiplimab 1Vinorelbine 1Pemetrexed 1Paclitaxel 1Gene Expression Profiling 1Gemcitabine 1Erlotinib Hydrochloride 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Non-Small Cell Lung Cancer × pemigatinib × Clear all
NCT05287386 2022-03-18

A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy

The First Affiliated Hospital of Xiamen University

Phase 2 Unknown
20 enrolled
Thoracic

Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡